Cite
HARVARD Citation
Valerio, L. et al. (2021). Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer. European thyroid journal. 10 (5), pp. 399-407. [Online].